The company estimates sales at $2 million in 2008.
Kamada Ltd. (TASE: KMDA) has won a tender by a Latin American government to supply its Kamrab rabies treatment. The company predicts $2 million in sales in 2008.
Kamada CEO David Tsur said that Kamrab was delivered by injection and that it had one of the best safety and hygiene records for rabies treatments. “The Center for Disease Control (CDC) noted in its conference last month in Atlanta to mark World Rabies Day that rabies kills 55,000 people a year, mostly in remote and isolated areas where there is no regular medical help. The CDC added that the US has had 7,000 cases of rabies so far this year. It is a privilege for us to save lives.”
Kamrab is developed from pooled human plasma with a high content of anti-rabies antibodies.
Published by Globes [online], Israel business news - www.globes.co.il - on October 23, 2007
© Copyright of Globes Publisher Itonut (1983) Ltd. 2007